President Trump is considering reclassifying marijuana from a highly restricted Schedule I drug to Schedule III, a move that could significantly impact the cannabis industry. This potential shift, aligning it with substances like Tylenol with codeine, promises to unlock research funding and ease banking access for cannabis businesses. The DEA will ultimately decide on the reclassification.